166 related articles for article (PubMed ID: 37204683)
41. Rituximab/bendamustine/cytarabine for transplant-eligible patients with mantle cell lymphoma: A retrospective study.
Shimizu Y; Kaji D; Watanabe O; Yamaguchi K; Kageyama K; Taya Y; Nishida A; Ishiwata K; Takagi S; Yamamoto H; Mori YA; Wake A; Uchida N; Taniguchi S; Yamamoto G
Cancer Med; 2023 Jun; 12(11):12548-12552. PubMed ID: 37199050
[TBL] [Abstract][Full Text] [Related]
42. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
[TBL] [Abstract][Full Text] [Related]
43. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
[TBL] [Abstract][Full Text] [Related]
44. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436
[TBL] [Abstract][Full Text] [Related]
45. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation.
Visco C; Finotto S; Zambello R; Paolini R; Menin A; Zanotti R; Zaja F; Semenzato G; Pizzolo G; D'Amore ES; Rodeghiero F
J Clin Oncol; 2013 Apr; 31(11):1442-9. PubMed ID: 23401442
[TBL] [Abstract][Full Text] [Related]
46. Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi.
Arcari A; Morello L; Vallisa D; Marcheselli L; Tecchio C; Quaglia FM; Tisi MC; Zilioli VR; Di Rocco A; Perrone T; Gini G; Dogliotti I; Bianchetti N; Bozzoli V; De Philippis C; Alvarez De Celis MI; Chiappella A; Fabbri A; Pelosini M; Merli M; Molinari AL; Sciarra R; Volpetti S; Hohaus S; Nassi L; Visco C
Leuk Lymphoma; 2021 Dec; 62(14):3474-3483. PubMed ID: 34625013
[TBL] [Abstract][Full Text] [Related]
47. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure.
Ayers EC; Li S; Medeiros LJ; Bond DA; Maddocks KJ; Torka P; Mier Hicks A; Curry M; Wagner-Johnston ND; Karmali R; Behdad A; Fakhri B; Kahl BS; Churnetski MC; Cohen JB; Reddy NM; Modi D; Ramchandren R; Howlett C; Leslie LA; Cytryn S; Diefenbach CS; Faramand R; Chavez JC; Olszewski AJ; Liu Y; Barta SK; Mukhija D; Hill BT; Ma H; Amengual JE; Nathan S; Assouline SE; Orellana-Noia VM; Portell CA; Chandar A; David KA; Giri A; Hess BT; Landsburg DJ
Cancer; 2020 Jan; 126(2):293-303. PubMed ID: 31568564
[TBL] [Abstract][Full Text] [Related]
48. Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma.
Klener P; Fronkova E; Belada D; Forsterova K; Pytlik R; Kalinova M; Simkovic M; Salek D; Mocikova H; Prochazka V; Blahovcova P; Janikova A; Markova J; Obr A; Berkova A; Kubinyi J; Vaskova M; Mejstrikova E; Campr V; Jaksa R; Kodet R; Michalova K; Trka J; Trneny M
Hematol Oncol; 2018 Feb; 36(1):110-115. PubMed ID: 29083050
[TBL] [Abstract][Full Text] [Related]
49. R-CHOP or R-HyperCVAD with or without autologous stem cell transplantation for older patients with mantle cell lymphoma.
Frosch Z; Luskin MR; Landsburg DJ; Schuster SJ; Svoboda J; Loren AW; Porter DL; Stadtmauer EA; Nasta SD
Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):92-7. PubMed ID: 25174772
[TBL] [Abstract][Full Text] [Related]
50. Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma.
Smith SD; Gandhy S; Gopal AK; Reddy P; Shadman M; Till BG; Lynch RC; Kanan S; Cowan A; Low L; Hill BT
Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):48-52. PubMed ID: 30409719
[TBL] [Abstract][Full Text] [Related]
51. The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial.
Roider T; Wang X; Hüttl K; Müller-Tidow C; Klapper W; Rosenwald A; Stewart JP; de Castro DG; Dreger P; Hermine O; Kluin-Nelemans HC; Grabe N; Dreyling M; Pott C; Ott G; Hoster E; Dietrich S
Int J Cancer; 2021 Jan; 148(1):150-160. PubMed ID: 32638373
[TBL] [Abstract][Full Text] [Related]
52. Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients.
McCulloch R; Lewis D; Crosbie N; Eyre TA; Bolam S; Arasaretnam A; Creasey T; Goradia H; McMillan A; Dawi S; Harrison S; Miles O; Robinson A; Dutton D; Wilson MR; McKay P; Follows G; Phillips N; Patmore R; Lambert J; Bishton M; Osborne W; Johnston R; Kirkwood AA; Rule S
Br J Haematol; 2021 Apr; 193(2):290-298. PubMed ID: 33620106
[TBL] [Abstract][Full Text] [Related]
53. Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
Klanova M; Lorkova L; Vit O; Maswabi B; Molinsky J; Pospisilova J; Vockova P; Mavis C; Lateckova L; Kulvait V; Vejmelkova D; Jaksa R; Hernandez F; Trneny M; Vokurka M; Petrak J; Klener P
Mol Cancer; 2014 Jun; 13():159. PubMed ID: 24972933
[TBL] [Abstract][Full Text] [Related]
54. Superiority of ibrutinib plus bendamustine and rituximab in newly diagnosed patients with mantle-cell lymphoma ineligible for intensive therapy: A network meta-analysis.
Sheng Z; Wang L
Eur J Haematol; 2023 Jun; 110(6):602-607. PubMed ID: 36919283
[TBL] [Abstract][Full Text] [Related]
55. Initial and Consolidation Therapy for Younger Patients with Mantle Cell Lymphoma.
Guy D; Kahl BS
Hematol Oncol Clin North Am; 2020 Oct; 34(5):861-870. PubMed ID: 32861283
[TBL] [Abstract][Full Text] [Related]
56. Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers.
Hueso T; Gastinne T; Garciaz S; Tchernonog E; Delette C; Casasnovas RO; Durot E; Houot R; Tessoulin B; Tournilhac O; Malak S; Gyan E; Fornecker LM; Abraham J; Delapierre B; Peyrade F; Lemal R; Gressin R; Chantepie S; Borel C; Morello R; Bouabdallah K; Ibrahim A; Bouabdallah R; Le Gouill S; Damaj G
Bone Marrow Transplant; 2020 Jun; 55(6):1076-1084. PubMed ID: 31953532
[TBL] [Abstract][Full Text] [Related]
57. Ixazomib With or Without Rituximab Following Maintenance Autologous Stem Cell Transplant in Mantle Cell Lymphoma: A Single-Center Phase I Trial.
Romancik JT; Chen Z; Allen PB; Waller EK; Valla K; Colbert A; Rosand C; Palmer AF; Flowers CR; Cohen JB
Clin Lymphoma Myeloma Leuk; 2022 Dec; 22(12):e1084-e1091. PubMed ID: 36180329
[TBL] [Abstract][Full Text] [Related]
58. RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106.
Chen RW; Li H; Bernstein SH; Kahwash S; Rimsza LM; Forman SJ; Constine L; Shea TC; Cashen AF; Blum KA; Fenske TS; Barr PM; Phillips T; Leblanc M; Fisher RI; Cheson BD; Smith SM; Faham M; Wilkins J; Leonard JP; Kahl BS; Friedberg JW
Br J Haematol; 2017 Mar; 176(5):759-769. PubMed ID: 27992063
[TBL] [Abstract][Full Text] [Related]
59. Mantle Cell Lymphoma: First-line Therapy in Patients Not Eligible for Stem Cell Transplantation.
Nazeef M; Kahl BS
Curr Treat Options Oncol; 2015 Jun; 16(6):29. PubMed ID: 25975443
[TBL] [Abstract][Full Text] [Related]
60. First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.
Flinn IW; van der Jagt R; Kahl B; Wood P; Hawkins T; MacDonald D; Simpson D; Kolibaba K; Issa S; Chang J; Trotman J; Hallman D; Chen L; Burke JM
J Clin Oncol; 2019 Apr; 37(12):984-991. PubMed ID: 30811293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
